Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2003
07/31/2003WO2003061553A2 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
07/31/2003WO2003061402A2 Reduction of renal damage in companion animals
07/31/2003WO2003061395A1 Ubiquinol-enriched fat-containing foods
07/31/2003WO2003061389A1 Antiseptic compositions and methods
07/31/2003WO2003061378A2 Synergistic mixtures of o-phenylphenol and other microbiocides
07/31/2003WO2003061362A2 Methods and compositions for treating polycystic ovary syndrome
07/31/2003WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators
07/31/2003WO2003053429A3 2-indanylamino derivatives for the therapy of chronic pain
07/31/2003WO2003047516A3 Pyrimidine compounds
07/31/2003WO2003041703A3 Use of a flavonoid for the treatment of burns
07/31/2003WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors
07/31/2003WO2003040339A3 Antisense modulation of purinoreceptor p2x¿3?
07/31/2003WO2003039460A3 Mitotic kinesin inhibitors
07/31/2003WO2003037253A3 Methods for the treatment and diagnosis of tumorigenic and angiogenic disorders using 32616
07/31/2003WO2003035668A3 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
07/31/2003WO2003034988A3 Injectable compositions for the controlled delivery of pharmacologically active compound
07/31/2003WO2003028696A3 Compositions for delivery of drug combinations
07/31/2003WO2003027061A3 Muscarinic agonists
07/31/2003WO2003026615A3 Modified release dosage forms
07/31/2003WO2003025140A3 Transductin-1 and transductin-2 and applications to hereditary deafness
07/31/2003WO2003024388A3 Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
07/31/2003WO2003020701A3 Multi-use multimodal imaging chelates
07/31/2003WO2003020677A3 C2-substituted indane-1-ones and their derivatives, method for their production and their use as medicaments
07/31/2003WO2003020242A9 Sustained release preparations
07/31/2003WO2003018545B1 24-sulfur-substituted analogs of 1α,25-dihydroxy vitamin d¿3?
07/31/2003WO2003016333A3 Virus coat protein/receptor chimeras and methods of use
07/31/2003WO2003015825A3 Conjugate
07/31/2003WO2003010139A3 Antisense modulation of hormone-sensitive lipase expression
07/31/2003WO2003007995A3 Pharmaceutical preparations containing ion exchange resins charged with fluoroquinolone
07/31/2003WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
07/31/2003WO2003002596A3 Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders
07/31/2003WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection
07/31/2003WO2003000023A3 Method of treating hyperproliferative diseases using active vitamin d analogues
07/31/2003WO2002101005A3 A g-protein coupled receptor and uses therefor
07/31/2003WO2002100408A3 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
07/31/2003WO2002099042A3 Cads as modifiers of the p53 pathway and methods of use
07/31/2003WO2002094767A3 Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
07/31/2003WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
07/31/2003WO2002092065A3 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
07/31/2003WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof
07/31/2003WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling
07/31/2003WO2002062762A3 Potassium channel openers
07/31/2003WO2002060892A8 Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
07/31/2003WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
07/31/2003WO2002051410A3 Phenylthiazole and thiazoline derivatives and their use as antiparasitics
07/31/2003WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins
07/31/2003WO2002043772A3 Water-soluble polymer conjugates of triazine derivatives
07/31/2003WO2002040471A9 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
07/31/2003WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer
07/31/2003WO2002036203A3 Azole containing compositions with enhanced antifungal activity
07/31/2003WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses
07/31/2003WO2002030514A3 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
07/31/2003WO2002024897A3 Conditionally replicating viral vectors and their use
07/31/2003WO2002018361A3 Compounds having activity as inhibitors of cytochrome p450rai
07/31/2003WO2002015895A3 Alpha-difluoromethylornithine (dfmo) use in the human prostate
07/31/2003WO2002012286A3 Stress proteins and peptides and methods of use thereof
07/31/2003WO2002004003A3 Composition for the treatment of osteoarthritis
07/31/2003WO2001034566A3 Protease inhibitors
07/31/2003US20030144727 Medical device for delivering biologically active material
07/31/2003US20030144701 Method and system for terminating an atrial arrhythmia
07/31/2003US20030144635 Method to use transdermal administration of androgens to the adnexa of the eye
07/31/2003US20030144532 Method of manufacture of 1,3-oxathiolane nucleosides
07/31/2003US20030144531 Preparing chirally pure S-enantiomers of alpha -amino acids comprising the steps of: a) preparing an organometallic reagent from an alkyl halide of the formula (R) 2CH(CH2)nCH2X; b) adding the organometallic reagent to carbon dioxide to form
07/31/2003US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their
07/31/2003US20030144526 Calcium receptor-active compounds
07/31/2003US20030144525 Conjugated aromatic compounds with a pyridine substituent
07/31/2003US20030144523 Epothilone derivatives, method for producing same and their pharmaceutical use
07/31/2003US20030144517 Chiral fluoroquinolone arginine salt forms
07/31/2003US20030144516 Crystalline form VII of cabergoline
07/31/2003US20030144510 Preparation of pharmaceutical salts
07/31/2003US20030144507 Sulfonamide-containing heterocyclic compounds
07/31/2003US20030144506 Formula 1 are useful in treating abnormal cell growth in mammals by administering pharmaceutical compositions.
07/31/2003US20030144503 Antiinflammatory agents
07/31/2003US20030144502 Induce apoptosis; anticancer agents
07/31/2003US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents
07/31/2003US20030144363 Hydroxystilbene compounds for reducing/inhibiting protein glycation
07/31/2003US20030144360 Synthetic bile acid receptor/ farnesoid x-activated receptor (bar/fxr) ligands agn 29 and agn 31 used as anticholesterol agents
07/31/2003US20030144359 Dermatological use and a dermatological preparation
07/31/2003US20030144357 Inhibition of glutamine synthetase; antiswelling and antiepileptic agents
07/31/2003US20030144356 Formulation
07/31/2003US20030144355 Stabilisation of pigments and polyunsaturated oils and oil concentrates
07/31/2003US20030144354 Composition for the prevention and/or treatment of the cytotoxic effects induced by the use of immunosuppressive agents
07/31/2003US20030144353 Functional acylglycerides
07/31/2003US20030144352 Antimuscarinic aerosol
07/31/2003US20030144351 Bruton's tyrosine kinase; contacting mast cells with a leukotriene altering amount of a leflunomide analog
07/31/2003US20030144350 Modulating fatty acid or triglyceride accumulation by cells; treating obesity and metabolic disorders
07/31/2003US20030144348 Muricin A, B, C, D, E, F, and G; antitumor agents
07/31/2003US20030144347 Method for treating autoimmune disease
07/31/2003US20030144346 Methods and compositions for regulation of 5-alpha reductase activity
07/31/2003US20030144344 Use as anti-tumor agents; examples of solvents are N-methyl-2-pyrrolidone and acetonitrile
07/31/2003US20030144343 To treat and/or prevent hypertension, cardiac hypertrophy, cardiac insufficiency, coronary heart diseases such as angina pectoris, and endothelial dysfunction or endothelial damage as a consequence of atherosclerotic processes or diabetes
07/31/2003US20030144341 Administering agent to lower serum cholesterol of patient enough to increase brain membrane fluidity adequately to treat cognitive or psychological disorder
07/31/2003US20030144340 By inhibiting fetal cardiac gene expression and interfering with sarcomeric organization
07/31/2003US20030144339 Treatment of inflammatory disease, arthritis, asthma
07/31/2003US20030144338 Pyrrole derivative
07/31/2003US20030144337 Pyrazole-derived kinase inhibitors and uses thereof
07/31/2003US20030144335 Nitroimidazole compound for allergic conjunctivitis or allergic rhinitis
07/31/2003US20030144334 Cyclopentabenzofuran derivatives and their use
07/31/2003US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
07/31/2003US20030144331 p53 inhibitors and therapeutic use of the same
1 ... 5389 5390 5391 5392 5393 5394 5395 5396 5397 5398 5399 5400 5401 5402 5403 5404 5405 5406 5407 5408 5409 ... 7860